BioSpace News Archive

Senti Bio today announced the addition of three independent experts to its Scientific Advisory Board (SAB).

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announces its intention to prioritize its focus to its oncology pipeline that includes QN-247 and RAS-F.

PolyPid Ltd. announced today that its Co-Founder and Chief Scientific Officer Dr. Noam Emanuel, will deliver a virtual presentation at the first World Association against Infection in Orthopaedics and Trauma (WAIOT) Congress on August 28, 2021.

PharmAbcine Inc. announced today that the Company will participate in Biotechgate Digital Partnering taking place virtually from August 30 – September 3, 2021 .

Sparrow Pharmaceuticals today announced the appointment of Frank Czerwiec, MD, PhD as Chief Medical Officer and Jamie MacPherson, PharmD as Vice President of Regulatory Affairs and Quality.

Incyte announced that it will present at the Morgan Stanley 19th Annual Global Healthcare Conference on Monday, September 13, 2021 at 11:45 a.m. ET.

Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announces that its manufacturing site in Cleveland, Ohio is now commercially operational and has released the first anti-infectives manufactured at the site, to be distributed for use by US hospitals.

nanoMesh™ LLC, a subsidiary of Exogenesis Corporation, today announced the formation of a Medical Advisory Board supporting the commercial launch of the nanoMesh™ product line offering to the clinical community.

Diamond Therapeutics Inc. is pleased to announce that it has received a No Objection Letter from Health Canada, allowing Diamond to proceed with a human clinical trial to evaluate low doses of psilocybin in healthy volunteers.

Receptor Life Sciences (RLS), a pharmaceutical company developing innovative therapies to address central nervous system disorders, announced the publication of a manuscript in the Journal of Pharmaceutical Sciences.